Rituximab in adult patients with immunosuppressive-dependent minimal change disease

Clinical Nephrology

Volumn 76, Issue 2, 2011, Pages 151-158

  Hoxha, E ^a   Stahl, R A K ^a   Harendza, S ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Frequent relapses; Minimal change disease; Rituximab

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LEVAMISOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTEIN; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE DEPENDENT MINIMAL CHANGE DISEASE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; MALE; NEPHROTIC SYNDROME; PROSPECTIVE STUDY; PROTEINURIA; RELAPSE; REMISSION; SINGLE DRUG DOSE;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROSIS, LIPOID; NEPHROTIC SYNDROME; PROSPECTIVE STUDIES; PROTEINURIA; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 80052365525     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107092     Document Type: Article

References (33)

1. Cameron JS. Nephrotic syndrome in the elderly. Semin Nephrol. 1996; 16: 319-329. PubMed
2. Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephritic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997; 30: 621-631. doi:10.1016/S0272-6386(97)90485-6 PubMed
3. Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? Kidney Int. 2009; 76: 487-491. doi: 10.1038/ki.2009.204 PubMed
4. Marasà M, Kopp JB. Monoclonal antibodies for podocytopathies: rationale and clinical responses. Nat Rev Nephrol. 2009; 5: 337-348. doi:10.1038/nrneph.2009.70 PubMed
5. Tejani AT, Butt K, Trachtman H, Suthanthiran M, Rosenthal CJ, Khawar MR. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int. 1988; 33: 729-734. doi:10.1038/ki.1988.59 PubMed
6. Wiederrecht G, Lam E, Hung S, Martin M, Sigal N. The mechanism of action of FK-506 and cyclosporine A. Ann N Y Acad Sci. 1993; 696: 9-19. doi:10.1111/j.1749-6632.1993.tb17137.x PubMed
7. Araya CE, Wasserfall CH, Brusko TM, Mu W, Segal MS, Johnson RJ, Garin EH. A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol. 2006; 21: 603-610. doi:10.1007/s00467-006-0026-5 PubMed
8. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001; 167: 4710-4718. PubMed
9. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by downregulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005; 52: 501-513. doi:10.1002/art.20858 PubMed
10. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007; 2: 445-453. doi:10.2215/CJN.03531006 PubMed
11. Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis. 2002; 39: 503-512. doi:10.1053/ajkd.2002.31400 PubMed
12. Cade R, Mars D, Privette M, Thompson R, Croker B, Peterson J, Campbell K. Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephritic syndrome resistant to corticosteroids. Arch Intern Med. 1986; 146: 737-741. doi:10.1001/archinte.146.4.737 PubMed
13. British Association for Paediatric Nephrology. Levamisole for corticosteroid-dependent nephritic syndrome in childhood. Lancet. 1991; 337: 1555-1557. PubMed
14. Kyrieleis HA, Löwik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, van den Heuvel BL, Wetzels JF, Levtchenko EN. Long-term outcome of biopsyproven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol. 2009; 4: 1593-1600. doi:10.2215/CJN.05691108 PubMed
15. Filler G, Young E, Geier P, Carpenter B, Drukker A, Feber J. Is there really an increase in nonminimal change nephrotic syndrome in children? Am J Kidney Dis. 2003; 42: 1107-1113. doi: 10.1053/j.ajkd.2003.08.010 PubMed
16. Bonilla-Felix M, Parra C, Dajani T, Ferris M, Swinford RD, Portman RJ, Verani R. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int. 1999; 55: 1885-1890. doi:10.1046/j.1523-1755. 1999. 00408.x PubMed
17. Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T, Kaneko K. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010; 25: 539-544. doi:10.1007/s00467-009-13 77- 5 PubMed
18. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F. Rituximab treatment for severe steroid- or cyclosporine-dependent nephritic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008; 23: 1269-1279. doi:10.1007/s00467-008-0814-1 PubMed
19. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009; 24: 1321-1328. doi:10.1007/s00467-009-1191-0 PubMed
20. François H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis. 2007; 49: 158-161. doi:10.1053/j.ajkd. 2006. 10.015 PubMed
21. Sawara Y, Itabashi M, Kojima C, Tabata H, Kamei D, Kawanishi K, Moriyama T, Sugiura H, Tsukada M, Takei T, Ogawa T, Yoshida T, Arai J, Uchida K, Tsuchiya K, Nitta K. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephritic syndrome. Clin Nephrol. 2009; 72: 69-72. PubMed
22. Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant. 2008; 23: 377-380. doi:10.1093/ndt/gfm592 PubMed
23. Kurosu N, Sugiura H, Iwasaki C, Asamiya Y, Kojima C, Moriyama T, Itabashi M, Tsukada M, Takei T, Ogawa T, Yoshida T, Uchida K, Tsuchiya K, Nitta K. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern Med. 2009; 48: 1901-1904. doi:10.2169/internalmedicine.48.2435 PubMed
24. Hofstra JM, Deegens JK, Wetzels JF. Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome? Nephrol Dial Transplant. 2007; 22: 2100-2102. doi:10.1093/ndt/gfm128 PubMed
25. Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C, Shiohira T, Shimizu A, Tsuruta Y, Amemiya N, Ogawa T, Uchida K, Tsuchiya K, Nitta K. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract. 2011; 117: c98-c105. doi: 10.1159/000319656 PubMed
26. Sellier-Leclerc AL, Macher MA, Loirat C, Guérin V, Watier H, Peuchmaur M, Baudouin V, Deschênes G. Rituximab efficiency in children with steroiddependent nephrotic syndrome. Pediatr Nephrol. 2010; 25: 1109-1115. doi: 10.1007/s00467-010-1465-6 PubMed
27. Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, Wilke N, Schmidt RE, Jacobs R. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 2009; 60: 3563-3571. doi:10.1002/art.24998 PubMed
28. Dantal J, Godfrin Y, Koll R, Perretto S, Naulet J, Bouhours JF, Soulillou JP. Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol. 1998; 9: 1709-1715. PubMed
29. Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, Hurault de Ligny B, Niaudet P, Charpentier B, Soulillou JP. Effect of plasma protein adsorption on protein excretion in kidneytransplant recipients with recurrent nephritic syndrome. N Engl J Med. 1994; 330: 7-14. doi:10.1056/NEJM199401063300102 PubMed
30. Kemper MJ, Meyer-Jark T, Lilova M, Müller- Wiefel DE. Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol. 2003; 60: 242-247. PubMed
31. Sakai K, Takasu J, Nihei H, Yonekura T, Aoki Y, Kawamura T, Mizuiri S, Aikawa A. Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient. Clin Transplant. 2010; 24 (Suppl 22): 60-65. doi:10.1111/j.1399-0012.2010.01279.x PubMed
32. El-Husseini A, El-Basuony F, Mahmoud I, Sheashaa H, Sabry A, Hassan R, Taha N, Hassan N, Sayed-Ahmad N, Sobh M. Long-term effects of cyclosporine in children with idiopathic nephritic syndrome: a single-centre experience. Nephrol Dial Transplant. 2005; 20: 2433-2438. doi:10. 1093/ndt/gfi059 PubMed
33. Kyrieleis HA, Levtchenko EN, Wetzels JF. Longterm outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis. 2007; 49: 592-597. doi:10.1053/j.ajkd.2007.02.270 PubMed